GMED Stock Analysis: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$76.64
-0.57 (-0.74%)
▼
5d:
-1.68%
30d:
-17.38%
90d:
-13.0%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 07, 2026
0d
Smart Money Accumulation
GMED is down 9.2% this week, but smart money is accumulating calls. Top strike: $90 2026-06-18 with 150 OI. Call ratio: 73% View Scanner →
Strength: 6.9/10
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GMED appears deeply undervalued. Market expects -8.7% annual earnings decline despite 67% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: GMED appears deeply undervalued. Market expects -8.7% annual earnings decline despite 67% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$137.07
Based on 6.4% avg growth
INTRINSIC VALUE TODAY
$85.11
10.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $76.64, which is considered oversold relative to its 30-day fair value range of $83.02 to $95.59. From a valuation perspective, the stock is trading at a discount (Forward PE: 15.0) compared to its historical average (19.7). Remarkably, the market is currently pricing in an annual earnings decline of 8.7% over the next few years. This pessimistic expectation contrasts with the company's recent 66.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMED is in a downtrend. The price is currently testing key support at $74.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $111.50 (+45.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMED is in a downtrend. The price is currently testing key support at $74.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $111.50 (+45.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$83.02 -
$95.59
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.5% below Wall St target ($111.50)
Trading Range Analysis
30-Day Trading Range
$83.02 -
$95.59
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$74.50
Resistance Level
$92.02
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.98
Wall Street Target
$111.50
(+45.5%)
Revenue Growth (YoY)
27.0%
Earnings Growth (YoY)
66.7%
Profit Margin
18.9%
Valuation Discount vs History
-8.7% cheaper
PE vs Historical
15.0 vs 19.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.7%
(market-implied from PE analysis)
1-Year Target
$69.97
(-9%)
2-Year Target
$63.88
(-17%)
3-Year Target
$58.33
(-24%)
3-Yr Target (if PE normalizes)
(PE: 15→20)
$76.73
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 8.7%)
$145.14
(+89%)
Base:
(SPY PE: 15.0, Growth: 8.7%)
$98.48
(+29%)
Bear:
(PE: 12.7, Growth: 8.7%)
$83.71
(+9%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 18.04 | Current EPS (TTM): $4.28
Bull Case
$101.55
(+33%)
Analyst growth 19.6%, PE expands to 19.8
Base Case
$92.32
(+21%)
Market implied 19.6%, PE stable at 18.0
Bear Case
$52.50
(-32%)
Severe decline -20.0%, PE contracts to 15.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.0 to 19.7
Stabilization Target:
$100.82
(+31.5%)
PE Expansion Potential:
+31.5%
Share & Embed Analysis
Last updated: May 18, 2026 5:05 AM ET
Data refreshes hourly during market hours. Next update: 6:05 AM
Data refreshes hourly during market hours. Next update: 6:05 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
1
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Gilbert Ray Cisneros, Jr.
BUY
2026-03-03
Kelly Huller
SELL
20000 shares
2026-02-25
Kelly Huller
SELL
10000 shares
2026-02-12
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$83 | 66 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$389 | 58 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$108 | 64 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$250 | 59 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 55 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
